To evaluate the safety and efficacy of carbon ion radiotherapy (C-ion RT) for 80 years or older patients with hepatocellular carcinoma (HCC).
Eligibility criteria of this retrospective study were: 1) HCC confirmed by histology or typical hallmarks of HCC by imaging techniques of four-phase multidetector-row computed tomography or dynamic contrast-enhanced magnetic resonance imaging; 2) no intrahepatic metastasis or distant metastasis; 3) no findings suggesting direct infiltration of the gastrointestinal tract; 4) performance status ≤2 by Eastern Cooperative Oncology Group classification; and 5) Child-Pugh classification A or B. Patients received C-ion RT with 52.8 Gy (RBE) or 60.0 Gy (RBE) in four fractions for usual cases and 60.0 Gy (RBE) in 12 fractions for close-to-gastrointestinal tract cases. Toxicities were classified using the National Cancer Institute’s Common Terminology Criteria for Adverse Events (Version 4.0).
Between March 2011 and November 2015, 31 patients were treated. The median follow-up period of all patients was 23.2 months (range: 8.4–55.3 months). Median age at the time of registration of C-ion RT was 83 years (range: 80–95 years). Child-Pugh grade A and B were 27 patients and 4 patients, respectively.
The 2-year estimated overall survival, local control, and progression-free survival rates were 82.3%, 89.2%, and 51.3%, respectively. No patients had Grade 2 or higher acute toxicities (within 3 months after C-ion RT). One patient experienced progression in Child-Pugh classification from A to B within 3 months after C-ion RT. In late toxicities, Grade 3 encephalopathy was observed in 3 patients, and 2 improved with medication.
C-ion RT was effective with minimal toxicities for 80 years or older patients with hepatocellular carcinoma.
UMIN000020571: date of registration, 14 January 2016, retrospectively registered.
Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet (London, England). 2012;379(9822):1245–55. CrossRef
Kumar V, Abbas Abdul K, Fausto NR. Cotran pathological basis of disease 7th edition. In: Saunders. 2005;
Imada H, Kato H, Yasuda S, Yamada S, Yanagi T, Kishimoto R, Kandatsu S, Mizoe JE, Kamada T, Yokosuka O, et al. Comparison of efficacy and toxicity of short-course carbon ion radiotherapy for hepatocellular carcinoma depending on their proximity to the porta hepatis. Radiother Oncol. 2010;96(2):231–5. CrossRefPubMed
Sobin LH, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours 7th ed: Wiley- Blackwell; 2011.
Singal AK, Kamath PS. Model for end-stage liver disease. J clin exp hepatology. 2013;3(1):50–60. CrossRef
Abe T, Shibuya K, Koyama Y, Okamoto M, Kiyohara H, Katoh H, Shimada H, Kuwano H, Ohno T, Nakano T. Initial results of Hypofractionated carbon ion radiotherapy for Cholangiocarcinoma. Anticancer Res. 2016;36(6):2955–60. PubMed
Health UDo, Services H: National cancer institute: common terminology criteria for adverse events (CTCAE), version 4.0. US Department of Health and Human Services National Institutes of health National Cancer Institute 2009.
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34. CrossRefPubMed
Nishikawa H, Osaki Y, Iguchi E, Takeda H, Ohara Y, Sakamoto A, Hatamaru K, Henmi S, Saito S, Nasu A, et al. Percutaneous radiofrequency ablation for hepatocellular carcinoma: clinical outcome and safety in elderly patients. J Gastrointestin Liver Dis. 2012;21(4):397–405. PubMed
- Carbon ion radiotherapy for 80 years or older patients with hepatocellular carcinoma
- BioMed Central
Neu im Fachgebiet Onkologie
Mail Icon II